HUMAN-RELEVANT DRUG SAFETY TESTING SERVICES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)
Segmentation
By Service TypeToxicity Testing Services · Organ-Specific Safety Assessment Services · Genotoxicity and Mutagenicity Testing Services · Safety Pharmacology Services. Model Validation and Regulatory Support Services
By Model TypeHuman Cell-Based Models · 3D Cell Culture Models and Organoids · Organ-on-Chip Models · Human Tissue-Based Models · Computational and In-Silico Models
By Therapeutic AreaOncology · Neurological Disorders · Cardiovascular Diseases · Metabolic and Liver Diseases · Infectious Diseases · Others
By ApplicationDrug Discovery and Development · Preclinical Toxicity Assessment · Drug-Induced Organ Toxicity Testing · Biologics and Advanced Therapy Safety Testing · Regulatory Safety Assessment · Others
By End UserPharmaceutical and Biotechnology Companies · Contract Research Organizations (CROs) · Academic and Research Institutions · Medical Device and Diagnostics Companies · Others
By GeographyNorth America · Latin America · Europe · Asia Pacific · Middle East · and Africa
Published In02 Nov 2026
Report CodeCMI10330
Pages250+
FormatsExcel and PDF
Base Year2025
Estimated Year2026
Historical Range2020 - 2024
Forecast Period2026-2033
Market Segmentation
Service Type Insights (Revenue, USD Bn, 2021 - 2033)
Toxicity Testing Services
Organ-Specific Safety Assessment Services
Genotoxicity and Mutagenicity Testing Services
Safety Pharmacology Services
Model Validation and Regulatory Support Services
Model Type Insights (Revenue, USD Bn, 2021 - 2033)
Human Cell-Based Models
3D Cell Culture Models and Organoids
Organ-on-Chip Models
Human Tissue-Based Models
Computational and In-Silico Models
Therapeutic Area Insights (Revenue, USD Bn, 2021 - 2033)
